Conventional MRI scans cannot evaluate disease-related changes in normal-appearing white matter, and have limited sensitivity for detecting changes in chronic lesions. In this work, we employed 2 quantitative MRI measures related to myelin content, myelin water fraction and magnetization transfer ratio, to evaluate the effects a potential novel therapy for multiple sclerosis (ocrelizumab) compared to a commonly-used therapy (interferon beta-1a). Over 2 years, these myelin-related measurements increased or remained stable in all regions for patients taking ocrelizumab, while they decreased for interferon beta-1a. These results support the use of quantitative MRI measures for more efficient, biologically specific clinical trial outcomes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords